Drug Pricing Evolution in Hepatitis C

Details

Serval ID
serval:BIB_8692970EA3F9
Type
Article: article from journal or magazin.
Collection
Publications
Title
Drug Pricing Evolution in Hepatitis C
Journal
PLoS One
Author(s)
Vernaz N., Girardin F., Goossens N., Brugger U., Riguzzi M., Perrier A., Negro F.
ISSN
1932-6203 (Electronic)
ISSN-L
1932-6203
Publication state
Published
Issued date
2016
Volume
11
Number
6
Pages
e0157098
Language
english
Notes
Vernaz, Nathalie
Girardin, Francois
Goossens, Nicolas
Brugger, Urs
Riguzzi, Marco
Perrier, Arnaud
Negro, Francesco
eng
PLoS One. 2016 Jun 16;11(6):e0157098. doi: 10.1371/journal.pone.0157098. eCollection 2016.
Abstract
OBJECTIVE: We aimed to determine the association between the stepwise increase in the sustained viral response (SVR) and Swiss and United States (US) market prices of drug regimens for treatment-naive, genotype 1 chronic hepatitis C virus (HCV) infection in the last 25 years. We identified the following five steps in the development of HCV treatment regimens: 1) interferon (IFN)-alpha monotherapy in the early '90s, 2) IFN-alpha in combination with ribavirin (RBV), 3) pegylated (peg) IFN-alpha in combination with RBV, 4) the first direct acting antivirals (DAAs) (telaprevir and boceprevir) in combination with pegIFN-alpha and RBV, and 5) newer DAA-based regimens, such as sofosbuvir (which is or is not combined with ledipasvir) and fixed-dose combination of ritonavir-boosted paritaprevir and ombitasvir in combination with dasabuvir. DESIGN: We performed a linear regression and mean cost analysis to test for an association between SVRs and HCV regimen prices. We conducted a sensitivity analysis using US prices at the time of US drug licensing. We selected randomized clinical trials of drugs approved for use in Switzerland from 1997 to July 2015 including treatment-naive patients with HCV genotype 1 infection. RESULTS: We identified a statistically significant positive relationship between the proportion of patients achieving SVRs and the costs of HCV regimens in Switzerland (with a bivariate ordinary least square regression yielding an R2 measure of 0.96) and the US (R2 = 0.95). The incremental cost per additional percentage of SVR was 597.14 USD in Switzerland and 1,063.81 USD in the US. CONCLUSION: The pricing of drugs for HCV regimens follows a value-based model, which has a stable ratio of costs per achieved SVR over 25 years. Health care systems are struggling with the high resource use of these new agents despite their obvious long-term advantages for the overall health of the population. Therefore, the pharmaceutical industry, health care payers and other stakeholders are challenged with finding new drug pricing schemes to treat the entire population infected with HCV.
Keywords
Antiviral Agents/*economics/therapeutic use, Cost-Benefit Analysis, Drug Discovery/economics, Drug Therapy, Combination/economics, Genotype, Hepacivirus/*drug effects, Hepatitis C/*drug therapy/*economics/epidemiology/virology, Humans, Interferons/economics/therapeutic use, Oligopeptides/economics/therapeutic use, Ribavirin/economics/therapeutic use, Ritonavir/economics/therapeutic use, Sofosbuvir/economics/therapeutic use, Switzerland/epidemiology, United States/epidemiology
Pubmed
Create date
10/02/2021 11:32
Last modification date
11/02/2021 6:26
Usage data